

## Claims :

1. In the method of therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO), the improvement consisting of administration of an LHRH antagonist in the form of a short-term induction treatment for a period of about 4 to 12 weeks to a patient in need of such treatment, whereby subsequently the administration of the LHRH antagonist is ceased.

10 2. A method according to claim 1 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.

15 3. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.

20 4. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.

25 5. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.

6. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.

30 7. A method according to claim 1 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an

analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.

8. A method according to claim 1 wherein the LHRH antagonist is administered starting in the early to mid follicular phase, preferably on cycle day one to three.

9. A method according to claim 1 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix, antide, abarelix and D-63153.

10. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to 10 mg per week.

11. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to 0.5 mg/day.

12. A method according to claim 1 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.

13. A method according to claim 1 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.

14. A pharmaceutical composition for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and/or fallopian tube obstruction (FTO) comprising an LHRH antagonist and optionally one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, optionally together with pharmaceutically acceptable excipients, whereby the LH-RH antagonist is administered to a patient in need thereof in a short term induction treatment for a

Applicant: ASIA Medica AG  
Applicant's ref. no.: 99/10PH/Ba

-22-

period of about 4 to 12 weeks, then the administration of the LH-RH antagonist is ceased and optionally the one or more agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are administered together or separately to the patient.

5 15. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered such that the estrogen serum concentration level is between

10 about 35 pg/ml and about 80 pg/ml, preferably between about 45-75 pg/ml, more preferably about 50-75 pg/ml.

15 16. Pharmaceutical composition according to claim 14 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a contraceptive, preferably an oral contraceptive.

20 17. Pharmaceutical composition according to claim 14 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of a non-steroidal anti-rheumatic agent.

18. Pharmaceutical composition according to claim 14 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an analgetic.

25 19. Pharmaceutical composition according to claim 14 wherein the short-term induction treatment with the LHRH antagonist is followed by administration of an androgen other than a 17-alpha-alkyl substituted testosterone.

30 20. Pharmaceutical composition according to claim 14 wherein the short-term induction treatment with the LHRH antagonist is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal

Applicant: ASTA Medica AG  
Applicant's ref. no.: 99/15 PH/Ba

-23-

anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof.

21. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist

5 is administered starting in the early to mid follicular phase, preferably on cycle day one to three.

22. A pharmaceutical composition according to claim 14 wherein the LHRH antagonist is selected from the group consisting of cetrorelix, teverelix, ganirelix,

10 antide, abarelix and D-63153.

23. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a weekly dose of about 3 to about 10 mg per week.

15

24. A pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a daily dose of about 0.25 mg to about 0.5 mg/day.

20 25. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is administered during the short-term induction treatment for about 4 to 12 weeks at a monthly dose of about 12 to 40 mg per month.

25 26. Pharmaceutical composition according to claim 14 wherein the LHRH antagonist is given for the induction treatment during about 4 to 12 weeks and the treatment is repeated two or three times a year.

30 27. Pharmaceutical composition according to claim 14, wherein the one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof, are in the same or separate dosage forms.

add A3